Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients

Abstract Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohamed A. Ismail, Marzia Vezzalini, Hisham Morsi, Ahmad Abujaber, Ali Al Sayab, Kodappully Siveen, Mohamed A. Yassin, Maria Monne, Muthanna Samara, Richard Cook, Claudio Sorio, Helmout Modjtahedi, Nader I. Al-Dewik
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6d88d7e906a945e29c80eab47db751fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d88d7e906a945e29c80eab47db751fc
record_format	dspace
spelling	oai:doaj.org-article:6d88d7e906a945e29c80eab47db751fc2021-12-02T15:26:58ZPredictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients10.1038/s41598-021-86875-y2045-2322https://doaj.org/article/6d88d7e906a945e29c80eab47db751fc2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86875-yhttps://doaj.org/toc/2045-2322Abstract Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TPγ B9-2) and RT-qPCR, and BCR-ABL1 transcript by RT-qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients.Mohamed A. IsmailMarzia VezzaliniHisham MorsiAhmad AbujaberAli Al SayabKodappully SiveenMohamed A. YassinMaria MonneMuthanna SamaraRichard CookClaudio SorioHelmout ModjtahediNader I. Al-DewikNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mohamed A. Ismail Marzia Vezzalini Hisham Morsi Ahmad Abujaber Ali Al Sayab Kodappully Siveen Mohamed A. Yassin Maria Monne Muthanna Samara Richard Cook Claudio Sorio Helmout Modjtahedi Nader I. Al-Dewik Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
description	Abstract Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TPγ B9-2) and RT-qPCR, and BCR-ABL1 transcript by RT-qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients.
format	article
author	Mohamed A. Ismail Marzia Vezzalini Hisham Morsi Ahmad Abujaber Ali Al Sayab Kodappully Siveen Mohamed A. Yassin Maria Monne Muthanna Samara Richard Cook Claudio Sorio Helmout Modjtahedi Nader I. Al-Dewik
author_facet	Mohamed A. Ismail Marzia Vezzalini Hisham Morsi Ahmad Abujaber Ali Al Sayab Kodappully Siveen Mohamed A. Yassin Maria Monne Muthanna Samara Richard Cook Claudio Sorio Helmout Modjtahedi Nader I. Al-Dewik
author_sort	Mohamed A. Ismail
title	Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
title_short	Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
title_full	Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
title_fullStr	Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
title_full_unstemmed	Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
title_sort	predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6d88d7e906a945e29c80eab47db751fc
work_keys_str_mv	AT mohamedaismail predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT marziavezzalini predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT hishammorsi predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT ahmadabujaber predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT alialsayab predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT kodappullysiveen predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT mohamedayassin predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT mariamonne predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT muthannasamara predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT richardcook predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT claudiosorio predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT helmoutmodjtahedi predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients AT naderialdewik predictivevalueoftyrosinephosphatasereceptorgammafortheresponsetotreatmenttyrosinekinaseinhibitorsinchronicmyeloidleukemiapatients
_version_	1718387207536902144

Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients

Ejemplares similares